Improvement of coronary flow velocity reserve with telmisartan in patients with autosomal-dominant polycystic kidney disease

Southern Medical Journal

Volumn 103, Issue 5, 2010, Pages 409-413

  Alisir, Sabahat ^a   Turkmen, Kultigin ^a   Alpay, Nilufer ^a   Elitok, Ali ^a   Oflaz, Huseyin ^a   Uslu, Bora ^a   Cimen, Arif ^a   Kasikcioglu, Erdem ^a   Tufan, Fatih ^a   Ecder, Tevfik ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; TELMISARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; CORONARY FLOW RESERVE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; KIDNEY POLYCYSTIC DISEASE; MALE; TREATMENT DURATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CORONARY CIRCULATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM;

EID: 77951790582     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181d80cae     Document Type: Article

References (33)

1. Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic Kidney Disease in Schrier RW (ed): Diseases of the Kidney and Urinary Tract. Philadelphia, PA, Lippincott Williams & Wilkins, 2007, ed 8, pp 502-539.
2. Fick GM, Johnson AM, Hammond WS, et al. Causes of death in auto-somal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5: 2048-2056.
3. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dom-inant polycystic kidney disease. Nat Rev Nephrol 2009;5:221-228.
4. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12:194-200. (Pubitemid 32056806)
5. Chapman AB, Johnson A, Gabow PA, et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-1096. (Pubitemid 20370729)
6. Harrap SB, Davies DL, Macnicol AM, et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501-508.
7. Barrett BJ, Foley R, Morgan J, et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:1118-1123. (Pubitemid 24319951)
8. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87:3C-9C.
9. Hirsch AT, Pinto YM, Schunkert H, et al. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D-30D; discussion 30D-32D. (Pubitemid 20352291)
10. Wolf G. Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant 1999;14 (suppl 1):42-44. (Pubitemid 29041836)
11. Chapman AB, Johnson AM, Rainguet S, et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-1297. (Pubitemid 27493634)
12. Valero FA, Martinez-Vea A, Bardají A, et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1020-1026. (Pubitemid 29203089)
13. Oflaz H, Alisir S, Buyukaydin B, et al. Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:2244-2249. (Pubitemid 43117800)
14. Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381-1388. (Pubitemid 37153804)
15. Kocaman O, Oflaz H, Yekeler E, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004;43:854-860. (Pubitemid 38529623)
16. Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998;97:1557-1562. (Pubitemid 28186183)
17. Rigo F. Coronary flow reserve in stressecho lab. From pathophysiologic toy to diagnostic tool. Cardivasc Ultrasound 2005;3:8. (Pubitemid 40727411)
18. Turkmen K, Oflaz H, Uslu B, et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 2008;3:986-991.
19. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343:824-827. (Pubitemid 24147512)
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Saggar-Malik AK, Missouris CG, Gill JS, et al. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. BMJ 1994;309:1617-1618.
22. Bardají A, Vea AM, Gutierrez C, et al. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998;32:970-975. (Pubitemid 28551159)
23. Zeier M, Geberth S, Schmidt KG, et al. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993;3:1451-1457.
24. Lüscher TF. Endothelial dysfunction: the role and impact of the renin-angiotensin system. Heart 2000;84(suppl 1):i20-i22; discussion i50.
25. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266. (Pubitemid 34875734)
26. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906. (Pubitemid 30225269)
27. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-954. (Pubitemid 30131694)
28. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-193. (Pubitemid 34084317)
29. Skalidis EI, Parthenakis FI, Patrianakos AP, et al. Regional coronary flow and contractile reserve in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004;44:2027-2032. (Pubitemid 39473289)
30. Cecchi F, Olivotto I, Gistri R, et al. Coronary microcircular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349: 1027-1035. (Pubitemid 37087617)
31. Yokoyama I, Momomura S, Ohtake T, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997;30:1472-1477. (Pubitemid 27486464)
32. Galiuto L, Sestito A, Barchetta S, et al. Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X. Am J Cardiol 2007;99:1378-1383. (Pubitemid 46686641)
33. Kamezaki F, Tasaki H, Yamashita K, et al. Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker. Hypertens Res 2007;30:699-706. (Pubitemid 47517103)